pioglitazone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 296 Diseases   92 Trials   92 Trials   3449 News 


«12...3637383940414243444546...4849»
  • ||||||||||  Tavegil (clemastine) / GSK
    Biomarker, Trial completion date, Trial primary completion date, Combination therapy:  Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) (clinicaltrials.gov) -  Apr 7, 2019   
    P1/2,  N=250, Recruiting, 
    EA intervention is able to improve the disorder of lipid metabolism of IR rats, which may be associated with its effects in lowering the activity of fatty acid synthesis-related enzymes and regulating AMPK/p38 MAPK/PPARγ signaling to improve IR in the liver tissue. Trial completion date: Jun 2030 --> Jan 2029 | Trial primary completion date: Jun 2030 --> Jan 2025
  • ||||||||||  Journal:  Regulation of the metabolism of apolipoprotein M and sphingosine 1-phosphate by hepatic PPARγ activity. (Pubmed Central) -  Apr 5, 2019   
    ...When we activated or suppressed the PPARγ more mildly with pioglitazone or GW9662, we found that pioglitazone suppressed apoM expression and S1P synthesis, while GW9662 increased them...Moreover, the overexpression of apoM increased, while the knockdown of apoM suppressed PPARγ activities in HepG2 cells. These results suggested that PPARγ regulates the S1P levels by modulating apoM in a bell-shaped manner, with the greatest levels of apoM/S1P observed when PPARγ was mildly expressed and that hepatic apoM/PPARγ axis might maintain the homeostasis of S1P metabolism.
  • ||||||||||  pioglitazone / generics
    Biomarker, Clinical, Journal:  Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. (Pubmed Central) -  Apr 5, 2019   
    ...Currently recommended therapies for NASH include vitamin E and pioglitazone, besides dietary and lifestyle changes...Furthermore, studies have determined that the Mediterranean diet is beneficial for patients with NAFLD, while the traditional Okinawan diet is also considered useful. In the future, it will be important to establish new biomarkers to assess NAFLD activity, furthermore non-invasive diagnostic methods will promote the development of new drugs for NASH.
  • ||||||||||  pioglitazone / generics
    Preclinical, Journal:  Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats. (Pubmed Central) -  Apr 5, 2019   
    In the future, it will be important to establish new biomarkers to assess NAFLD activity, furthermore non-invasive diagnostic methods will promote the development of new drugs for NASH. Our findings suggest that PPARG activation plays important roles in modulating early ovarian function, and highlight the importance of understanding the role(s) of PPARG activation in the ovary, and the possible involvement in the treatment of ovarian pathologies, and/or the impact in regulating/improving fertility.
  • ||||||||||  pioglitazone / generics
    Journal:  Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis. (Pubmed Central) -  Mar 25, 2019   
    Furthermore, facilitation of the autophagic flux by pioglitazone was obviously blocked by lysosomal inhibitor, leupeptin, to demonstrate accumulation of the LC3II and intracellular lipid in AML12 cells. Our results demonstrated that pioglitazone attenuating the hepatic steatosis may be mediated by enhancing cytosolic lipolysis, β-oxidation and autophagy in a PPARα and PPARγ dependent manner.
  • ||||||||||  U0126 / Promega, PD98059 / Wayne State University
    Journal:  Egr-1 mediates leptin-induced PPARγ reduction and proliferation of pulmonary artery smooth muscle cells. (Pubmed Central) -  Mar 25, 2019   
    In addition, activation of PPARγ by pioglitazone or targeting ERK1/2/Egr-1 suppressed leptin-induced PASMC proliferation. Taken together, our study indicates that ERK1/2 signaling pathway mediated leptin-induced PPARγ reduction and PASMC proliferation through up-regulation of Egr-1, and suggests that targeting leptin/ERK1/2/Egr-1 pathway might have potential value in ameliorating vascular remodeling and benefit PH.
  • ||||||||||  pioglitazone / generics
    Clinical, Journal:  Early life adversity blunts responses to pioglitazone in depressed, overweight adults. (Pubmed Central) -  Mar 25, 2019   
    Taken together, our study indicates that ERK1/2 signaling pathway mediated leptin-induced PPARγ reduction and PASMC proliferation through up-regulation of Egr-1, and suggests that targeting leptin/ERK1/2/Egr-1 pathway might have potential value in ameliorating vascular remodeling and benefit PH. We conclude that a history of early life adversity may impair the body's ability to respond to insulin sensitizing pharmacotherapy, and furthermore that its contribution to resistant depression may function in part via the generation of an insulin resistant phenotype.
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    New P4 trial:  Dapagliflozin Plus Pioglitazone in T1DM (clinicaltrials.gov) -  Mar 18, 2019   
    P4,  N=120, Not yet recruiting, 
  • ||||||||||  MK-3655 / Merck (MSD)
    Trial completion, Trial completion date, Trial primary completion date:  Study of NGM313 in Obese Participants (clinicaltrials.gov) -  Mar 13, 2019   
    P1b,  N=25, Completed, 
    The FTIR method has been successfully applied for the determination of the cited binary mixtures in its pharmaceutical tablets and the obtained results showed satisfactory % recovery. Recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jun 2018
  • ||||||||||  pioglitazone / Generic mfg.
    Trial completion date:  Preventing Squamous Cell Skin Cancer (clinicaltrials.gov) -  Feb 18, 2019   
    P2,  N=40, Enrolling by invitation, 
    45 mg is a safe dose to use in future efficacy trials. Trial completion date: Dec 2018 --> Dec 2019
  • ||||||||||  pioglitazone / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  PioPAP: Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis (clinicaltrials.gov) -  Feb 1, 2019   
    P1,  N=3, Active, not recruiting, 
    Not yet recruiting --> Active, not recruiting | Initiation date: Jan 2019 --> Jan 2018 Recruiting --> Active, not recruiting | Trial completion date: Jul 2018 --> Jun 2020 | Trial primary completion date: Jul 2018 --> Jun 2019
  • ||||||||||  pioglitazone / Generic mfg., clomifene citrate / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome (clinicaltrials.gov) -  Jan 15, 2019   
    P1,  N=400, Not yet recruiting, 
    Initiation date: Jan 2019 --> Aug 2019 Trial completion date: Dec 2018 --> May 2019 | Initiation date: Jun 2018 --> Jan 2019 | Trial primary completion date: Nov 2018 --> Apr 2019
  • ||||||||||  pioglitazone / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia (clinicaltrials.gov) -  Jan 9, 2019   
    P2,  N=9, Terminated, 
    Initiation date: Sep 2018 --> Jan 2019 N=26 --> 9 | Trial completion date: May 2021 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: May 2021 --> Jul 2018
  • ||||||||||  pioglitazone / Generic mfg.
    Biomarker, Trial completion:  Pharmacogenomics of Thiazolidinediones (clinicaltrials.gov) -  Sep 27, 2018   
    P=N/A,  N=134, Completed, 
    Trial completion date: Jan 2019 --> Aug 2019 Enrolling by invitation --> Completed
  • ||||||||||  pioglitazone / Generic mfg.
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI (clinicaltrials.gov) -  Aug 8, 2018   
    P2,  N=0, Withdrawn, 
    Trial completion date: Jul 2019 --> Aug 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Aug 2018; Lack of efficacy of the drug; no safety concern N=30 --> 0 | Trial completion date: Dec 2019 --> Apr 2018 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2019 --> Apr 2018
  • ||||||||||  pioglitazone / Generic mfg.
    Enrollment change, Trial completion date, Immunomodulating:  Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE) (clinicaltrials.gov) -  Jul 30, 2018   
    P1/2,  N=100, Recruiting, 
    N=30 --> 0 | Trial completion date: Dec 2019 --> Apr 2018 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2019 --> Apr 2018 N=70 --> 100 | Trial completion date: Jan 2020 --> Jun 2020
  • ||||||||||  Myrbetriq (mirabegron) / Astellas
    Enrollment open, Trial completion date:  Brown Fat Activation Study (clinicaltrials.gov) -  Jun 25, 2018   
    P1,  N=75, Recruiting, 
    Recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Dec 2019 --> Dec 2020
  • ||||||||||  rosiglitazone / Generic mfg.
    Journal:  Autologous fat transplants to deliver glitazone and adiponectin for vasculoprotection. (Pubmed Central) -  Jun 8, 2018   
    External jugular vein exposed to fat incorporated with PGZ had increased adiponectin expression compared to vein exposed to fat alone. However, the development of hyperplasia within the arteriovenous synthetic grafts was unchanged by treatment with fat/PGZ depots compared to no treatment.
  • ||||||||||  pioglitazone / Generic mfg.
    Phase classification, Enrollment change, Trial completion date, Trial termination:  Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study) (clinicaltrials.gov) -  Jun 2, 2018   
    P4,  N=630, Terminated, 
    However, the development of hyperplasia within the arteriovenous synthetic grafts was unchanged by treatment with fat/PGZ depots compared to no treatment. Phase classification: P=N/A --> P4 | N=3000 --> 630 | Trial completion date: Apr 2009 --> Apr 2018 | Recruiting --> Terminated; Limited budget to continue this study
  • ||||||||||  hydroxychloroquine / Generic mfg., metformin / Generic mfg., pioglitazone / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus (clinicaltrials.gov) -  Jun 1, 2018   
    P2,  N=17, Terminated, 
    Phase classification: P=N/A --> P4 | N=3000 --> 630 | Trial completion date: Apr 2009 --> Apr 2018 | Recruiting --> Terminated; Limited budget to continue this study N=60 --> 17 | Trial completion date: Feb 2018 --> Nov 2017 | Recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Nov 2017; Investigator decision
  • ||||||||||  pioglitazone / Generic mfg.
    Enrollment open:  Study of Pioglitazone in Sporadic Inclusion Body Myositis (clinicaltrials.gov) -  May 31, 2018   
    P1,  N=15, Recruiting, 
    N=60 --> 17 | Trial completion date: Feb 2018 --> Nov 2017 | Recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Nov 2017; Investigator decision Not yet recruiting --> Recruiting
  • ||||||||||  pioglitazone / Generic mfg.
    Enrollment open:  Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients (clinicaltrials.gov) -  May 1, 2018   
    P4,  N=28, Recruiting, 
    N=149 --> 40 | Trial completion date: Apr 2021 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2021 --> May 2018; Lack of efficacy of the drug; no safety concern Not yet recruiting --> Recruiting
  • ||||||||||  pioglitazone / Generic mfg.
    Enrollment change:  Pioglitazone to Treat Opioid Withdrawal Symptoms (clinicaltrials.gov) -  Apr 6, 2018   
    P1,  N=24, Terminated, 
    Not yet recruiting --> Recruiting N=120 --> 24